HLX01 vs Rituximab-abbs (Truxima)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: CD20 · full Rheumatoid Arthritis pipeline

HLX01 · Hanlikang

Marketed by Shanghai Henlius Biotech

Phase 3 in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT03522415 · Phase 3 · completed

This randomised, quadruple-blind trial compared HLX01 plus methotrexate with placebo plus methotrexate in 275 patients with rheumatoid arthritis. At 24 weeks, 60.7% of patients on HLX01 reached an ACR20 response against 35.9% on placebo (P<0.001), a clear result on a validated measure of disease activity.

No aligned efficacy figure on record for this race.

Rituximab-abbs (Truxima)

Marketed by Celltrion and partners

Approved in Rheumatoid Arthritismonoclonal antibody
Reliable signal

NCT02149121 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with an adequately sized population (384 enrolled) that pre-specified formal equivalence margins for both its pharmacokinetic and its clinical disease-activity (DAS28-CRP) primary endpoints, and every comparison landed entirely within the required margin, meaning the biosimilar demonstrated therapeutic equivalence to the reference product on a validated hard clinical measure of rheumatoid arthritis activity, not just a proxy lab value.

Reported efficacy

Analysis of Serum AUC0-last of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA); Analysis of Serum AUC0-inf of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Serum Cmax of Rituximab During the 1st Course of the Main Study Period (Over the First 24 Weeks) (ANCOVA) (at Week 24 of the Main Study Period); Analysis of Change From Baseline of DAS28 (CRP) at Week 24 (ANCOVA) (at Week 24 of the Main Study Period): Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%). (met)

Result source: NCT02149121

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointHLX01Rituximab-abbs (Truxima)
ACR2060.7% vs 35.9%a+24.8 vs placebowk 24NCT03522415—Not reported
ACR50—Not posted · NCT03522415—Not reported
ACR70—Not posted · NCT03522415—Not reported
DAS28-CRP remission—Not posted · NCT03522415—Not reported
HAQ-DI, change—Not posted · NCT03522415—Not reported
Modified Sharp score, change—Not posted · NCT03522415—Not reported

ACR20

HLX01
60.7% vs 35.9%a+24.8 vs placebowk 24NCT03522415
Rituximab-abbs (Truxima)
—Not reported

ACR50

HLX01
—Not posted · NCT03522415
Rituximab-abbs (Truxima)
—Not reported

ACR70

HLX01
—Not posted · NCT03522415
Rituximab-abbs (Truxima)
—Not reported

DAS28-CRP remission

HLX01
—Not posted · NCT03522415
Rituximab-abbs (Truxima)
—Not reported

HAQ-DI, change

HLX01
—Not posted · NCT03522415
Rituximab-abbs (Truxima)
—Not reported

Modified Sharp score, change

HLX01
—Not posted · NCT03522415
Rituximab-abbs (Truxima)
—Not reported
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. HLX01: 0 of 4 rows · Rituximab-abbs (Truxima): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricHLX01Rituximab-abbs (Truxima)
Dropout rate—
13%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
—CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Discontinued due to AEs—
1.2%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
—CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Serious AEs—
8.1%CT-P10 (Main Study Period)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
3.3%CT-P10/CT-P10 (Extension Study Per
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
Most frequent reported AEs—
infusion-related reaction 20.5%
upper respiratory tract infection 14.9%
urinary tract infection 9.3%
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 1 more result
upper respiratory tract infection 8.2%
urinary tract infection 6.6%
infusion-related reaction 3.3%
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

HLX01

ACR20 60.7% vs 35.9% placebo @ 24wk
responder rate · % of participants
NCT03522415 · Phase 3 · sponsor-reported, not registry data

Rituximab-abbs (Truxima)

DAS28-CRP -2.11 vs -2.1 Reference Products score @ 24wk
absolute change · score
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 3 more results
5.8 vs 5.8 Rituxan score @ 0wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.3 vs -2.3 Rituxan score @ 24wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.7 vs -2.6 Rituxan score @ 48wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-CRP -3 vs -3 Rituxan score @ 24wk
absolute change · score
Extension (open-label)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-ESR 6.7 vs 6.7 Rituxan score @ 0wk
absolute change · score
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
show 2 more results
-2.5 vs -2.5 Rituxan score @ 24wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
-2.9 vs -2.8 Rituxan score @ 48wk
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3
DAS28-ESR -3.3 vs -3.3 Rituxan score @ 24wk
absolute change · score
Extension (open-label)
NCT02149121 · Phase 3 · Rheumatoid Arthritis · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX01's landscape · Rituximab-abbs (Truxima)'s landscape